Physician profile

Lesley E Maples

Physician Assistant · Colquitt, GA

NPI 1578566121

$917.51

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$236.85

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $278.31 2022-2023
Novo Nordisk INC $235.39 2021-2022
Astrazeneca Pharmaceuticals Lp $133.87 2021-2024 Farxiga
Abbvie INC. $114.30 2021
Lilly USA, LLC $56.06 2022
Glaxosmithkline, LLC. $40.46 2021
Boehringer Ingelheim Pharmaceuticals, INC. $25.08 2021
Csl Behring $19.38 2022
Alexion Pharmaceuticals, INC. $14.66 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lesley E Maples

$917.51

in general payments reported 2019-2025

Years
2021-2024
Top company
Bayer Healthcare Pharmaceuticals INC.

https://glasscript.com/doctor/10604371/lesley-e-maples

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.